-
Deferoxamine (DeferoxamineB) Assay Guide
2026-09-10
Learn how Deferoxamine (DeferoxamineB), SKU BA2746, can improve interpretation of iron-dependent viability, proliferation, and regulated cell-death assays. This scenario-based guide covers mechanistic controls, stock preparation, metabolic confounding, and practical product-selection criteria.
-
Partial BACE Inhibition and Synaptic Transmission
2026-09-09
Satir et al. showed that moderate β-secretase (BACE) inhibition can reduce amyloid β secretion by up to approximately 50% without measurably impairing synaptic transmission in primary cortical neuronal cultures. The study defines a potentially useful exposure window for prevention-oriented Alzheimer’s disease research while showing that stronger BACE inhibition can compromise neuronal function.
-
Network Medicine and Apigenin in Alzheimer’s Disease
2026-09-09
A 2025 study used network medicine to screen flavonoids by their proximity to Alzheimer’s disease targets, prioritizing Apigenin as the strongest candidate among four experimentally tested compounds. Computational predictions and cell-based validation linked Apigenin with protection against mitochondrial dysfunction, apoptosis, and microglia-driven neuroinflammation, while also identifying AKT1 and NFKBIA as important candidate targets.
-
Drug Response Measurement in Cancer: Schwartz's Study
2026-09-08
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth inhibition and cell killing should not be treated as interchangeable drug-response endpoints. The framework offers practical guidance for time-aware in vitro cancer research, including studies of mitotic agents and cell cycle arrest in mitosis.
-
Protease and Phosphatase Inhibitor Cocktail Workflow
2026-09-08
Protect total protein and phosphorylation-dependent readouts with an EDTA-free, 100X workflow designed for rapid extraction from cells, tissues, and microbial samples. The protocol also shows how preserved lysates can strengthen chamber-specific cardiomyocyte studies without confusing sample protection with cell differentiation.
-
BRD4770: G9a Histone Methyltransferase Inhibitor
2026-09-07
BRD4770 is a research-focused G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence and cancer-cell growth phenotypes. This guide translates its PANC-1 evidence into practical dosing, chromatin, proliferation, and troubleshooting workflows while placing the compound’s mechanism alongside a breast-cancer study of the c-MYC–G9a axis.
-
Tranexamic Acid: From Mechanism to Assay Design
2026-09-05
Tranexamic Acid is an antifibrinolytic agent whose effects depend on when and where plasmin activity is measured. This guide converts its molecular mechanism and recent wound-dressing evidence into practical assay-design decisions for reproducible fibrinolysis research.
-
DiR Maps Cell Therapy from Membrane to Mechanism
2026-09-05
DiR (DiIC 18 (7)) can help translational researchers connect hUC-MSC biodistribution with the β-NGF–STMN2/NMNAT2–SARM1/NF-κB mechanism implicated in perioperative neurocognitive disorders. This thought-leadership article outlines a validation strategy that treats membrane fluorescence as a decision-support layer rather than a substitute for functional and molecular evidence.
-
Erastin Workflows for Ferroptosis Research
2026-09-04
Use Erastin as a practical ferroptosis inducer to expose redox vulnerabilities in RAS- or BRAF-altered tumor models. This guide combines an actionable treatment workflow with oxidative stress readouts, cross-domain interpretation, and troubleshooting based on recent ferroptosis research.
-
Itraconazole and the Biofilm Resistance Bottleneck
2026-09-04
Itraconazole is more than a triazole antifungal agent: it is a translational probe for linking Candida biofilm resistance, CYP3A4-mediated drug interactions, and signaling biology. This article interprets recent PP2A–autophagy findings while defining a rigorous, exposure-aware strategy for extending them without overstating itraconazole-specific evidence.
-
Simeprevir and Novobiocin Against SFTSV
2026-09-03
A 2025 Journal of Medical Virology study screened 19 FDA-approved drugs and identified simeprevir, Novobiocin, and levofloxacin hydrochloride as in vitro inhibitors of severe fever with thrombocytopenia syndrome virus. The work illustrates how cell-based phenotypic screening plus immunofluorescence confirmation can prioritize repurposing candidates while also showing why cytotoxicity, mechanism, pharmacokinetics, and in vivo validation remain essential.
-
LMO2–LDB1 Signaling in AML: Study Analysis
2026-09-03
The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia cell maintenance, linking LDB1-dependent transcriptional regulation with apoptosis and proliferation. Its combination of gene perturbation, protein-interaction analysis, transcriptomics, chromatin profiling, and rescue experiments provides a useful framework for evaluating transcriptional co-regulators as AML targets.
-
Taxus chinensis Fruit and TLR4 in Neuroinflammation
2026-09-02
The reference study shows that Taxus chinensis fruit extract attenuates aging-related behavioral changes and neuroinflammation by suppressing microglial activation through the TLR4/NF-κB/NLRP3 axis. Its integrated animal, cellular, chemical, and computational design provides a useful framework for investigating plant-derived modulators of inflammatory signaling while highlighting important limits in causal and translational interpretation.
-
Annexin V-APC/7-AAD Apoptosis Kit Workflow
2026-09-02
Build a rapid, two-parameter workflow to distinguish viable, early apoptotic, late apoptotic, and necrotic cells in cancer and immunology models. The Annexin V-APC/7-AAD Apoptosis Kit combines phosphatidylserine detection with membrane-integrity readout, making it useful for treatment time courses, dose-response studies, and mechanistic follow-up.
-
Dehydroabietic Acid in Adipocyte Metabolic Assays
2026-09-01
Use Dehydroabietic acid as a controllable pharmacological complement to adipocyte CRISPRi experiments, rather than treating gene silencing and receptor activation as interchangeable tools. This workflow connects PPAR-driven lipid metabolism regulation with Fabp4-focused studies of inflammation, steatosis, and insulin sensitivity.